GRI Bio Receives Notice Of Allowance In The UAE For Patent Covering Novel Type 2 Diverse NKT Cell Agonists For Treating Inflammatory Conditions

GRI Bio, Inc., a biotechnology company developing a pipeline of Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office for UAE Patent No. P6000687/2017, titled “Prevention and Treatment of Inflammatory Conditions.”

The newly allowed claims cover novel type 2 diverse NKT (dNKT) cell agonists, along with related methods and compositions intended for preventing and treating inflammatory conditions. This patent expands GRI Bio’s intellectual property protection around its proprietary immunomodulatory platform and supports therapeutic strategies focused on modulating immune pathways linked to inflammatory, fibrotic, and autoimmune diseases. The allowance also reinforces the company’s long-term global IP strategy, which aims to secure broad exclusivity and maintain strategic flexibility across key markets.

The UAE is a growing and strategically important healthcare market and serves as a central hub for the broader Middle East and North Africa (MENA) region. Obtaining patent protection in this jurisdiction strengthens GRI Bio’s global IP position for its dNKT cell agonist program and enhances its ability to pursue future partnerships, licensing discussions, and commercial pathways in the region.

Marc Hertz, Chief Executive Officer of GRI Bio, stated that the Notice of Allowance reflects continued progress in executing the company’s worldwide intellectual property strategy. He emphasized that securing protection in major international markets not only fortifies the company’s scientific platform but also supports pipeline development and contributes to long-term value creation for shareholders.

The allowed patent aligns with GRI Bio’s broader platform focused on modulating NKT cell activity—an emerging therapeutic approach designed to regulate immune responses across diseases where current treatment options remain limited. This patent further strengthens the durability and reach of the company’s global IP portfolio.

GRI Bio continues to advance its lead program, GRI-0621, while leveraging its expanding chemistry platform and library of more than 500 proprietary compounds to support future pipeline opportunities and potential strategic collaborations.